|Bid||7.58 x 1000|
|Ask||7.63 x 800|
|Day's range||7.51 - 7.81|
|52-week range||6.07 - 15.86|
|Beta (5Y monthly)||1.58|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||26 Nov 2017|
|1y target est||11.67|
Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $7.90, moving +0.77% from the previous trading session.
Malaria drug, chloroquine, is being tested for the treatment of patients infected with COVID-19. Generic makers, Mylan and Teva ramp up efforts to contribute to the same.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today the immediate donation of more than 6 million doses of hydroxychloroquine sulfate tablets through wholesalers to hospitals across the U.S. to meet the urgent demand for the medicine as an investigational target to treat COVID-19. The company is also looking at additional ways to address the global need.
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Celltrion Healthcare, Co., Ltd. (KRX KOSDAQ:091990), today announced that HERZUMA®1 (trastuzumab-pkrb) for Injection, a biosimilar to HERCEPTIN®1, is now available in the United States with the same indications as the reference product including:
Teva Pharmaceutical Europe BV an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the National Institute for Health and Care Excellence (NICE) has recommended AJOVY (fremanezumab) in its Final Appraisal Document (FAD) for the prevention of migraine in adults with chronic migraine. NICE recommends AJOVY® for chronic migraine patients who have not responded to at least three prior preventive drug treatments.
U.S. stock indexes ticked slightly higher on Tuesday as investors dipped their toes in the water a day after worries about the the worldwide spread of the coronavirus sent the S&P 500 and the Dow Industrials to their biggest daily declines in two years. Department store operator Macy's Inc also fell 1% even after a smaller-than-expected drop in quarterly same-store sales.
U.S. stock index futures edged higher on Tuesday, helped by a slate of positive earnings, a day after the S&P 500 and the Dow Industrials logged their worst session in two years on worries over the worldwide spread of the virus. Shares of Dow-member Home Depot Inc rose 2.5% in premarket trading after the home improvement chain beat quarterly sales and profit estimates. Another upbeat report in the retail space was from department store operator Macy's Inc, which jumped more than 5% after a smaller-than-expected drop in quarterly same-store sales.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Bayer Aktiengesellschaft, Pfizer, Mylan N.V. and Teva Pharmaceutical Industries
Teva Respiratory, LLC, an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved ArmonAir® Digihaler™ (fluticasone propionate) Inhalation Powder, an inhaled corticosteroid (ICS) delivered via Teva’s Digihaler™ device, which contains built-in sensors and connects to a companion mobile application that provides information on inhaler use to people with asthma. ArmonAir® Digihaler™ is indicated for the maintenance treatment of asthma in patients 12 years and older. ArmonAir® Digihaler™ is not indicated for the relief of acute bronchospasm.
The global reliance on China for APIs and drug manufacturing might hit supply chains and production amid the Coronavirus outbreak. Thus, companies independent of China's input are up for grabs now.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) released a new economic impact report detailing the billions of dollars saved by Teva’s generic medicines and the company’s impact on the US and global economies in 2018.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced positive results from two Phase 2/3 trials evaluating AJOVY® (fremanezumab) in patients in Japan. AJOVY is under development in Japan by Otsuka Pharmaceutical Co., Ltd. (Otsuka) as part of a May 2017 exclusive license agreement for development and sales of AJOVY in Japan.
Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
A new partnership plans to bolster the U.S. supply of generic drugs, as part of a wide ranging effort to help drive down spiking costs and ease shortages.
Years into a bond market bull-run, investors are banking on a brighter future for funds that buy the debt of financially troubled European companies whose bonds are offering meatier returns because they are more risky. With European economic growth expected to be subdued in 2020, and default rates tipped to rise, investors expect an increase in the number of companies that will struggle to service their debt. Private equity groups and asset managers are creating so-called special situation funds to identify suitable targets for these high-risk - and potentially high-reward - bets.
Novartis' (NVS) MS drug, Mayzent, obtains approval in Europe for the treatment of adult patients with secondary progressive multiple sclerosis.